#AI In Oncology Sales market

[sanskruti01]

Generative AI in Healthcare Market to Grow at an 35.1% CAGR Till 2032!

The global Generative AI in Healthcare Market worth USD 1.07 billion in 2023 is likely to be USD 21.74 billion by 2032, growing at a 35.1% CAGR between 2023 and 2032.

According to the stats published by World Health Organization (WHO), approximately 1.28 million adults (between 30 and 79 years of age) have hypertension. Of these, as little as 42% of adults are diagnosed and treated correctly and the remaining population is unaware of this condition. The majority of this population resides in low to middle-income countries of the world. Despite this substantial number of untreated cases, the rising awareness among doctors and the general population regarding health illnesses associated with hypertension is expected to drive the demand for the required devices.

Download White Paper@ https://www.towardshealthcare.com/personalized-scope/5069

A recent report provides crucial insights along with application based and forecast information in the Global Generative AI in Healthcare Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this Market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Generative AI in Healthcare Market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the Market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Report Objectives

To define, describe, and forecast the global Generative AI in Healthcare Market based on product, and region

To provide detailed information regarding the major factors influencing the growth of the Market (drivers, opportunities, and industry-specific challenges)

To strategically analyze microMarkets1 with respect to individual growth trends, future prospects, and contributions to the total Market

To analyze opportunities in the Market for stakeholders and provide details of the competitive landscape for Market leaders

To forecast the size of Market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2

To strategically profile key players and comprehensively analyze their product portfolios, Market shares, and core competencies3

To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the Generative AI in Healthcare Market

Companies and Manufacturers Covered

The study covers key players operating in the Market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Generative AI in Healthcare Market are included as given below:

Generative AI in Healthcare Market Key Players:

Syntegra

NioyaTech

Saxon

IBM Watson

Microsoft Corporation

Google LLC

Tencent Holdings Ltd.

Neuralink Corporation

OpenAI

Oracle

Market Segments :

By Application

Clinical

Cardiovascular

Dermatology

Infectious Disease

Oncology

Others

System

Disease Diagnosis

Telemedicine

Electronic Health Records

Drug Interaction

By Function

AI-Assisted Robotic Surgery

Virtual Nursing Assistants

Aid Clinical Judgment/Diagnosis

Workflow & Administrative Tasks

Image Analysis

By End User

Hospitals & Clinics

Clinical Research

Healthcare Organizations

Diagnostic Centers

Others

By Geography

North America

Europe

Asia-Pacific

Latin America

Middle East and Africa

Contact US -

Towards Healthcare

Web: https://www.towardshealthcare.com/

You can place an order or ask any questions, please feel free to contact at 

Email:  sales@towardshealthcare.com

About Us

We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

[rohitpalan]

Advanced (3D/4D) Visualization Systems Market Surges: Revenue Reaches USD 711.1M in 2022, Expected to Hit USD 1,139.9M by 2033

The global Advanced (3D/4D) Visualization Systems Market demonstrated remarkable growth in 2022, with a total revenue of US$ 711.1 million. This sector is poised for a promising future, as it is projected to expand at a CAGR of 4.5% from 2023 to 2033. By the end of the forecast period in 2033, the market is expected to reach a substantial US$ 1,139.9 million.

Key Takeaways:

The Advanced (3D/4D) Visualization Systems Market is on a growth trajectory, projected to reach US$ 1,139.9 million by 2033, driven by factors such as advanced medical imaging adoption and AI integration.

North America leads the market, while Asia-Pacific presents significant growth opportunities.

Challenges include high implementation costs and data security concerns.

Emerging technologies like VR and AR offer promising prospects for market players.

Drivers and Opportunities:

The growth of the Advanced (3D/4D) Visualization Systems Market can be attributed to several key drivers. The increasing adoption of advanced medical imaging techniques and the rising demand for real-time data visualization in healthcare are significant factors fueling this market’s growth. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) in 3D/4D visualization systems is enhancing diagnostic capabilities and driving market expansion.

Moreover, opportunities abound as the market taps into emerging technologies, including virtual reality (VR) and augmented reality (AR), which are revolutionizing industries such as healthcare, aerospace, and automotive. These innovations are opening new avenues for market players to develop cutting-edge visualization solutions.

Competitive Landscape – Regional Trends:

The Advanced (3D/4D) Visualization Systems Market boasts a competitive landscape with several key players vying for dominance. Regional trends reveal varying market dynamics. North America currently leads the market due to its advanced healthcare infrastructure and substantial investments in research and development. Meanwhile, Asia-Pacific is witnessing rapid growth, driven by increasing healthcare expenditure and a burgeoning demand for advanced visualization technologies in countries like China and India.

Restraints:

Despite its growth prospects, the market faces certain challenges. The high cost of implementing advanced visualization systems and concerns related to data security are restraining factors. Additionally, the complexity of integrating these systems into existing healthcare workflows poses a challenge for market adoption.

Region-wise Insights – Category-wise Insights:

North America remains the dominant region in the Advanced (3D/4D) Visualization Systems Market, with the United States leading the way. The region benefits from a robust healthcare infrastructure and significant investments in research and development.

Europe is witnessing steady growth, with countries like Germany and the United Kingdom contributing significantly to the market. The region’s focus on improving healthcare outcomes through advanced visualization technologies is driving market expansion.

Asia-Pacific is emerging as a lucrative market, driven by the increasing healthcare expenditure in countries like China and India. The demand for 3D/4D visualization systems in diagnostics and treatment planning is on the rise.

Advanced (3D/4D) Visualization Systems Outlook by Category

By Platform, Advanced (3D/4D) Visualization Systems Demand is segmented as:

Ultrasound

MRI

CT

PET

By End User, Advanced (3D/4D) Visualization Systems Outlook is segmented as:

Hospitals

Diagnostic Laboratories

Academic and Research

By Application, Advanced (3D/4D) Visualization Systems Sales are segmented as:

Cardiology

Oncology

Neurology

By Region, Advanced (3D/4D) Visualization Systems Sales are segmented as:

North America

Latin America

Europe

South Asia

East Asia

Oceania

The Middle East and Africa (MEA)

[grapheneai]

Benchmarking in Healthcare: Deciding Smarter with AI

In the world of healthcare, the adoption of Artificial Intelligence (AI) is reshaping how pharmaceutical companies make critical decisions. AI’s ability to sift through substantial amounts of data and generate insights with unparalleled speed is becoming a key differentiator.  

One of the most significant areas where AI is proving invaluable is benchmarking in healthcare, where companies can compare their performance against competitors using advanced analytics and unbiased feedback. 

AI’s Role in Healthcare Insights 

For pharmaceutical companies, insights are no longer about numbers—they are about understanding the patient experience, prescriber preferences, and the healthcare provider’s perspective on therapies. Traditional data sources like surveys and reports are being enhanced by GrapheneAI, which processes vast amounts of data using Natural Language Processing (NLP) and statistical models. Complex healthcare feedback is turned into understandable insights that drive smarter decision-making. 

GrapheneAI’s ability to provide unbiased insights from healthcare providers, patients, and even non-users gives pharmaceutical companies a clearer understanding of the market landscape. This understanding is crucial when it comes to answering critical business questions about the effectiveness of existing treatments or the potential of upcoming therapies. 

Benchmarking in Healthcare with AI: Why It Matters? 

Benchmarking in healthcare research traditionally involves comparing performance metrics across organizations to gauge effectiveness, efficiency, and overall impact. However, AI-enhanced benchmarking takes this concept further by leveraging external feedback sources and synthesizing them with internal company data. This advanced form of benchmarking allows organizations to: 

Understand Awareness and Perceptions 

Healthcare research involves gathering data on awareness, beliefs, drivers, and barriers to treatment amongst both HCPs as well as patients. AI helps to aggregate and analyze these factors, whether it is for rare diseases, oncology, or chronic conditions. 

Evaluate User Experience 

Combining internal patient data with external feedback provides a holistic view of how users perceive and experience products. AI tools help track patient journeys, from diagnosis to treatment adherence, offering real-time insights into where therapy may be excelling or lagging. 

Uncover Competitive Intelligence 

AI can track what patients, prescribers, and non-users are saying about your brand and your competitors in real-time. Through sophisticated sentiment analysis, companies can better understand market perceptions and brand reputation, converting them into actionable intelligence. 

Competitive Benchmarking in Healthcare: How It Works? 

Pharmaceutical companies are always looking for ways to outperform their competition, especially in highly competitive therapeutic areas. AI-driven competitive benchmarking allows companies to monitor key performance indicators (KPIs) in real-time. Here is how it works: 

1. Combining Internal and External Data 

By combining proprietary company data (such as sales, prescription rates, or clinical outcomes) with AI-analyzed external feedback (user reviews, social media sentiment, discussion forums, reactions to scientific publications), companies get a comprehensive view of their position in the market. 

2. Identifying Drivers of Success 

AI can pinpoint which factors contribute most to a product being rated highly in each category. For example, in oncology, patients might value efficacy over side effects, while in chronic disease management, ease of use may be a bigger priority. AI helps identify and weigh these factors, revealing actionable insights. 

3. Real-Time Market Positioning 

AI systems can provide continuous feedback on how a company’s product is performing against its competitors in terms of perception, prescription habits, and patient outcomes. Companies can see where they lead and where they fall behind, enabling quick adjustments to marketing or product strategies. 

4. Proactive Decision-Making 

With AI-enhanced benchmarking in healthcare, companies can anticipate changes in market dynamics or patient preferences, allowing for proactive strategy development rather than reactive fixes. 

Uncovering Insights for Business Growth 

At the heart of AI-powered benchmarking in healthcare is the ability to translate unbiased opinions into actionable insights. This can provide pharmaceutical companies with a competitive edge, offering visibility into what patients and providers value most and how their brand is perceived in comparison to competitors. Armed with this knowledge, businesses can tailor their strategies to meet market demands more effectively. 

Additionally, these insights can guide product development, optimize marketing campaigns, and improve the patient experience by aligning product offerings more closely with what the market needs. 

Decide Faster with Benchmarking in Healthcare 

Pharmaceutical companies that embrace AI-driven benchmarking will be better equipped to understand their place in the market, adapt to emerging trends, and, most importantly, make smarter, data-driven decisions that lead to improved patient outcomes and business success. In a competitive landscape where the margin for error is slim, AI is not just an advantage—it is a necessity. 

Contact us at GrapheneAI to benchmark not just on financial or operational metrics but also on the quality of care, patient satisfaction, and market perception. 

[omshinde5145]

Image-guided Radiation Therapy (IGRT) Market Share, Sales Channels and Overview Till 2030

The Image-guided Radiation Therapy (IGRT) Market is expected to grow from USD 1.7 billion in 2023-e to USD 2.4 billion by 2030, at a CAGR of 5.3% during the forecast period. Image-Guided Radiation Therapy (IGRT) is an advanced form of radiation therapy that uses imaging techniques to precisely target cancer cells. The image-guided radiation therapy (IGRT) market is expected to grow significantly due to the ability of IGRT to deliver precise doses at the site of action and improve patient outcomes with reduced time of therapy. The accuracy of radiation therapy is increased when cutting-edge imaging technologies are incorporated into the treatment plan. This is especially crucial when treating tumors in motion-prone areas such as the prostate or lungs that are close to important structures.

IGRT is a medical procedure used in radiation oncology to target malignant tumors with therapeutic radiation with the least amount of damage to the surrounding healthy tissues. The integration of imaging technologies with the planning and delivery of radiation therapy treatment is the fundamental component of IGRT. This guarantees that, even in cases where the tumor position varies as a result of factors such as organ motion, anatomical changes in the patient, or respiratory motion, the radiation is precisely targeted to the tumor.

Download a Sample Copy of This Report- https://intentmarketresearch.com/request-sample/image-guided-radiation-therapy-market-3030.html

The IGRT market is influenced by several key factors:

Technological Advancements:

Continuous innovation in imaging and radiation delivery systems is driving the IGRT market forward. Enhanced imaging techniques, such as cone-beam CT, MRI, and PET scans, are enabling more precise tumor localization and treatment planning.

Integration of artificial intelligence (AI) and machine learning (ML) in IGRT systems is further optimizing treatment accuracy and efficiency. AI-powered algorithms can predict tumor movements and adjust radiation doses in real-time, ensuring optimal treatment outcomes.

Rising Cancer Prevalence:

The global burden of cancer is increasing, with millions of new cases diagnosed each year. This rise in cancer incidence is fueling the demand for advanced treatment options like IGRT.

According to the World Health Organization (WHO), the global cancer burden is expected to reach 27.5 million new cases by 2040. This surge underscores the critical need for effective and precise treatments, making IGRT a vital component of modern oncology.

Increased Healthcare Spending:

Governments and healthcare organizations are investing heavily in advanced medical technologies to improve cancer care. This increased funding is facilitating the adoption of IGRT systems in hospitals and cancer treatment centers worldwide.

Public and private healthcare insurers are recognizing the long-term benefits of IGRT in terms of improved patient outcomes and reduced healthcare costs, leading to broader reimbursement policies and greater accessibility.

Growing Awareness and Acceptance:

Awareness campaigns and educational initiatives are highlighting the benefits of IGRT among patients and healthcare providers. As more people become informed about the advantages of this technology, the demand for IGRT is steadily rising.

Professional organizations and regulatory bodies are endorsing IGRT as a standard practice in radiation therapy, further driving its adoption.

Market Segmentation

The IGRT market can be segmented based on technology, application, end-user, and region:

Technology:

Cone-Beam Computed Tomography (CBCT)

Electronic Portal Imaging Devices (EPID)

MRI-guided Radiation Therapy

Positron Emission Tomography (PET)

Application:

Lung Cancer

Prostate Cancer

Breast Cancer

Head and Neck Cancer

Others

End-User:

Hospitals

Ambulatory Radiotherapy Centers

Cancer Research Institutes

Region:

North America

Europe

Asia-Pacific

Latin America

Middle East & Africa

Get Customization on this Report: https://intentmarketresearch.com/ask-for-customization/image-guided-radiation-therapy-market-3030.html

Future Prospects

The future of the IGRT market looks promising, driven by ongoing research and development, technological innovations, and increasing adoption of precision medicine. Key trends to watch in the coming years include:

Advancements in Imaging Technology:

Continuous improvements in imaging modalities will enhance the accuracy and efficacy of IGRT. High-resolution imaging and real-time monitoring will become more sophisticated, allowing for even more precise targeting of tumors.

Integration of AI and ML:

The integration of AI and ML will revolutionize IGRT by enabling adaptive radiation therapy. AI algorithms will predict tumor responses, adjust treatment plans dynamically, and minimize radiation exposure to healthy tissues.

Personalized Cancer Treatment:

Precision medicine will play a crucial role in IGRT, tailoring treatments to individual patients based on genetic profiles, tumor characteristics, and treatment responses. This personalized approach will improve treatment outcomes and reduce side effects.

Global Expansion:

The IGRT market will expand globally, with emerging economies adopting advanced cancer treatment technologies. Increased healthcare infrastructure and government support will drive market growth in regions like Asia-Pacific and Latin America.

Conclusion

Image-Guided Radiation Therapy (IGRT) represents a significant leap forward in cancer treatment, offering unparalleled precision and effectiveness. The IGRT market is poised for substantial growth, driven by technological advancements, rising cancer prevalence, increased healthcare spending, and growing awareness. As we look to the future, continued innovation and integration of cutting-edge technologies will further enhance the capabilities of IGRT, ultimately transforming the landscape of cancer care and improving the lives of countless patients worldwide.

[themarketupdate]

AI In Oncology Market Detailed Strategies, Competitive Landscaping and Developments for next 5 years

Latest added AI In Oncology Market research study by Archive Market Research offers detailed outlook and elaborates market review till 2030. The market Study is segmented by key regions that are accelerating the marketization. At present, the market players are strategizing and overcoming challenges of current scenario; some of the key players in the study are Azra AI,IBM,Siemens Healthcare GmbH,Intel Corporation,GE HealthCare,NVIDIA Corporation,Digital Diagnostics Inc.,ConcertAI,Median Technologies,PathAI} etc.  Click for Free Sample Report + All Related Graphs & Charts https://archivemarketresearch.com/report/ai-in-oncology-market-2449/sample-report The AI In Oncology Market size was valued at USD 4.18 billion in 2023 and is projected to reach USD 24.74 billion by 2032, exhibiting a CAGR of 28.92 % during the forecasts period. The latest edition of this report you will be entitled to receive additional chapter / commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation. Each of the segment analysis table for forecast period also high % impact on growth. The Global AI In Oncology segments and Market Data Break Down are illuminated below: {"Component Type: Software Solutions, Hardware","Cancer Type: Breast Cancer, Lung Cancer"}

Have Any Questions Regarding Global AI In Oncology Market Report, Ask Our Experts@ https://archivemarketresearch.com/report/ai-in-oncology-market-2449/enquiry-before-buy This report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market. Thanks for reading this article, we can also provide customized report as per company’s specific needs. You can also get separate chapter wise or region wise report versions including North America, Europe or Asia.

More Reports:

 https://archivemarketresearch.com/reports/ai-in-oncology-market-2449  https://archivemarketresearch.com/reports/veterinary-software-market-2444 Contact US : Craig Francis (PR & Marketing Manager) Archive Market Research Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[jcmarchi]

Absci and AstraZeneca forge AI partnership to discover cancer treatments

New Post has been published on https://thedigitalinsider.com/absci-and-astrazeneca-forge-ai-partnership-to-discover-cancer-treatments/

Absci and AstraZeneca forge AI partnership to discover cancer treatments

.pp-multiple-authors-boxes-wrapper display:none; img width:100%;

Absci, a frontrunner in generative AI antibody discovery, has partnered with biopharmaceutical giant AstraZeneca to leverage AI in the quest for a novel cancer treatment.

This collaboration will capitalise on Absci’s Integrated Drug Creation platform—seamlessly integrating with AstraZeneca’s expertise in oncology, aiming to expedite the discovery of a potentially game-changing cancer therapy.

Under the agreement, Absci will deploy its pioneering generative AI technology to craft a therapeutic candidate antibody tailored for a specific oncology target. The collaboration encompasses an upfront commitment, substantial R&D funding, milestone payments, and royalties on future product sales.

Sean McClain, Founder & CEO of Absci, said: “AstraZeneca is a leader in developing novel treatments in oncology, and we are excited to collaborate with them to design a therapeutic candidate antibody with the potential to improve the lives of cancer patients.”

Absci’s Integrated Drug Creation platform combines generative AI and scalable wet-lab technologies, generating proprietary data by scrutinising millions of protein-protein interactions. This data fuels Absci’s proprietary AI models, facilitating the design of antibodies that are later validated through wet-lab experiments.

This accelerated approach, completing the entire cycle within approximately six weeks, enhances the probability of successful development outcomes for biologic drug candidates.

Puja Sapra, PhD, SVP of Biologics Engineering & Oncology Targeted Delivery at AstraZeneca, commented: “This collaboration is an exciting opportunity to utilise Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology.”

The announcement follows Absci’s recent publication on the design and validation of de novo antibodies using their state-of-the-art ‘zero-shot’ generative AI model.

The collaboration between Absci and AstraZeneca should further help to demonstrate how AI can be used to revolutionise drug discovery.

(Photo by National Cancer Institute on Unsplash)

See also: AI & Big Data Expo: AI’s impact on decision-making in marketing

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is co-located with Cyber Security & Cloud Expo and Digital Transformation Week.

Explore other upcoming enterprise technology events and webinars powered by TechForge here.

Tags: absci, ai, artificial intelligence, astrazeneca, cancer, cancer therapy, cancer treatment, health, healthcare, treatment

[organicmarketresearch1]

Global Active Pharmaceutical Ingredients (API) Market 2022-2032

An active ingredient (AI) is the ingredient in a pharmaceutical drug that is biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active are also used in medicine, and the term active substance may be used for natural products. Some medication products may contain more than one active ingredient. The traditional word for the API is pharmacon or pharmakon which originally denoted a magical substance or drug.

India is the largest region of Active Pharmaceutical Ingredients (API), with a market share about 30%. Teva Active Pharmaceutical Industries Limited, DSM, Novartis, Roche and Johnson and Johnson are the top 5 manufacturers of industry.

The Global Active Pharmaceutical Ingredients API Market Size was estimated at USD 67774.47 million in 2021 and is projected to reach USD 127217.78 million by 2028, exhibiting a CAGR of 6.60% during the forecast period.

This report provides a deep insight into the global Active Pharmaceutical Ingredients API market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

Download Free Sample Report

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Active Pharmaceutical Ingredients API Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Active Pharmaceutical Ingredients API market in any manner.

Global Active Pharmaceutical Ingredients API Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

•Teva

•Mylan

•DSM

•Aurobindo Pharma

•Aspen

•Novartis

•BASF

•Pfizer

•Huahai Pharmaceutical

•Hisun Pharmaceutical

•Sun Pharmaceutical Industries

•Zhejiang Medicine

•Dr. Reddy’s Laboratories

•Zhejiang NHU

•Bayer

•NCPC

•AbbVie

•Shandong Xinhua Pharmaceutical

•Northeast Pharm

•Harbin Pharmaceutical

•LKPC

Market Segmentation (by Type)

•Synthetic APIs

•Biotech APIs

Market Segmentation (by Application)

•CNS

•Cardiovascular

•Genitourinary/Hormonal Drugs

•Respiratory

•Rheumatology

•Diabetes

•Oncology

•Others

Geographic Segmentation

• North America (USA, Canada, Mexico)

• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

• South America (Brazil, Argentina, Columbia, Rest of South America)

• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study

• Neutral perspective on the market performance

• Recent industry trends and developments

• Competitive landscape & strategies of key players

• Potential & niche segments and regions exhibiting promising growth covered

• Historical, current, and projected market size, in terms of value

• In-depth analysis of the Active Pharmaceutical Ingredients API Market

• Overview of the regional outlook of the Active Pharmaceutical Ingredients API Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

• This enables you to anticipate market changes to remain ahead of your competitors

• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

• Provision of market value (USD Billion) data for each segment and sub-segment

• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

• Provides insight into the market through Value Chain

• Market dynamics scenario, along with growth opportunities of the market in the years to come

• 6-month post-sales analyst support

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Active Pharmaceutical Ingredients API Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market’s Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter’s five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

About Us:

Organic Market Research Business Consulting is a fast-growing Market Research organization which is helping organizations to optimize their end-to-end research processes and increase their profit margins.

Organic Market Research facilitates clients with syndicate research reports and customized research reports on 10+ industries with global as well as regional coverage.

Mob : +91 9319642100

Noida One Tower Sec 62 Noida 201301

Sales : sales@organicmarketresearch.com

Website : https://www.organicmarketresearch.com

[bigfandeer]

Artificial Intelligence for Drug Development and Discovery Market Expected to Reach US$2,015.1 Million by 2025

Overview

The AI in drug discovery market is projected to grow by US$2,015.1 Million by 2025 rapidly at a CAGR of 40.8% throughout the forecast period 2019 to 2025. Integration of AI and machine learning tools as well as huge investments drive the global AI in drug discovery market. These key growth drivers have incredibly helped the AI in drug discovery market and are estimated to boost the growth. Analysts studying the AI in drug discovery market have also shared growth projections in the AI in drug discovery market research report and have suggested AI in drug discovery market-based companies to develop growth strategies. The high cost of AI integration and lack of infrastructure are the challenges that companies across the AI in drug discovery market could face. The details covered in the AI in drug discovery market report cover all the aspects of the industry.

Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/9393

Market Segmentation

The global AI in the drug discovery market has been segmented based on product type, technology, indication, molecule type, application, and end-user. On the basis of product type, the market for AI in drug discovery is segmented based on software and services. Additionally, the market on the basis of molecule type, is segmented into large molecule and small molecule. The global market for AI in drug discovery is also covered based on the technology segment which is further split into machine learning, deep learning and others. On the basis of indication, the market for AI in drug discovery is segmented based on cardiovascular diseases, metabolic diseases, neurodegenerative diseases, immuno-oncology, and others. Additionally, the market on the basis of end-user, is segmented into contract research organizations and research centers and academic & government institutes, pharmaceutical & biotechnology companies. The market is further segmented based on application into candidate screening, de novo drug designing, drug optimization and repurposing and preclinical testing, target identification.

Factors like increasing number of cross-industry partnerships and discovery of new pharmaceuticals propel the AI in drug discovery market growth. The AI in drug discovery market performance has also been studied. The AI in drug discovery market report provides analysis of past and current trends. In addition to this, the AI in drug discovery market report offers detailed analysis of application, indication, molecule type, technology, product type, and end-user segments. The market segmental analysis provided in the AI in drug discovery market research report offers crucial details about the AI in drug discovery market based on the data and forecasts till 2025.

Regional Overview

The AI in drug discovery market report covers companies functional in the AI in drug discovery market spread across regional markets of North America, Europe, Asia-Pacific (APAC), and the rest of the world. The regional analysis of the AI in drug discovery market can be found in the market research report. The North American AI in drug discovery market has several key players functioning in the United States, Canada, and Mexico. Europe has companies in the AI in drug discovery market across Germany, France, Spain, Italy, and the United Kingdom. The AI in drug discovery market of the Middle East, Africa, and other regions has also been studied by analysts. A detailed analysis of the AI in drug discovery market across India, China, and Japan in the Asia-Pacific region is also available for further study.

Competitive Landscape

The AI in drug discovery market is corroborated by improvement in the drug development. The population growth as well as increasing demand of AI in drug discovery market based solutions also accelerate the market growth. However, the AI in drug discovery market can be affected due to lack of developed infrastructure as well as high cost involved in deployment. The AI in drug discovery market research report covers all such factors assisting companies in the AI in drug discovery market to improve their plans and portfolio. The AI in drug discovery market research report also provides company profiles of major businesses. The AI in drug discovery market report highlights crucial details about organizations operating across North America, Europe, Asia-Pacific (APAC), and the rest of the world regional markets. The details available in the AI in drug discovery market report cover company strategies, revenue, company size, and mergers and acquisitions in the AI in drug discovery market. New entrants as well as established organizations can use the data from AI in drug discovery market report to further plan their strategies.

Industry News

ByteDance, the Chinese parent organization of TikTok, is joining the health sector as it aims to diversify a market that focuses on sales of ads and livestreaming. The firm, which is proud of content analytics, has begun to search talent in Mountain View, Shanghai and Beijing for AI drug exploration, its hiring page reveals.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/ai-drug-discovery-market-9393

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

[sanpdr1994]

Oncology Information Systems Market 2022 Production Capacity, Restring Drivers, Size and Landscape Outlook 2032

The Broadening Healthcare IT Industry Will Generate New Opportunity to Promote the Oncology Information System Market to USD 16.02 Billion by 2032. The oncology information system market has been divided into two segments: solutions and professional services. Solutions accounted for the majority of revenue i.e. 73.4%.

The oncology information system market is expected to expand at a 7.8% CAGR. The oncology information system market is expected to grow from USD 2.59 billion in 2022 to USD 5.48 billion by 2032.

The increasing incidence and prevalence of cancer, as well as the growing need to reduce the cost of cancer care, are driving the oncology information system market growth, as are the potential benefits offered by oncology information systems in cancer treatment, management, and planning.

The oncology information system market includes software and services used for comprehensive information and image management, which aids in the management and optimization of cancer patient profiles and treatment.

Leading oncology information system market players' sales and operating incomes have decreased as a result of COVID-19. Inventory was reduced as a result of tight production controls.

Get Sample PDF Of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15150

The rising incidence of cancer cases is one of the major factors driving the oncology information system market growth. There are a few other factors driving the oncology information system market key trends and opportunities, such as the growing need to reduce oncology care costs and the growing adoption of oncology information system along with electronic health records (EHR) and other oncology information systems.

A major impediment to implementing OIS solutions in hospitals is a lack of qualified resources influencing the oncology information system market future trends along with oncology information system market opportunities. Currently, the demand for healthcare IT professionals outnumbers supply in both developing and developed oncology information system market, including the United States and Europe.

Asia Pacific accounted for 17.8% of the oncology information system market. The Asia Pacific oncology information system market is expanding due to several factors, including rising cancer prevalence and increased investment in the implementation of IT solutions in healthcare settings which h influences the oncology information system market adoption trends.

KEY TAKEAWAYS:

The oncology information system market has been divided into two segments: solutions and professional services. The solutions segment accounted for the majority of revenue i.e. 73.4%.

The solutions segment is further subdivided into patient information systems and treatment planning systems, with the latter accounting for the lion's oncology information system market share.

Medical oncology accounted for the largest oncology information system market share of global revenue, accounting for 61.4% of total revenue.

In 2021, the North America regional oncology information system market had the highest oncology information system market share's revenue of 38.5%.

The software segment accounted for 83.6% of the product and service oncology information system market.

Radiation oncology accounted for 53.8% of the oncology information system market.

Asia Pacific accounted for 17.8% of the oncology information system market.

COMPETITIVE LANDSCAPE:

Key oncology information system market companies are primarily focused on incorporating technological innovation with the introduction of web-based oncology solutions and AI-based oncology information system solutions with the goal of improving the treatment regime, which is expected to positively impact oncology information system market growth in the near future.

Elekta AB, Accuray Inc., Varian Medical Systems, RaySearch Laboratories, Cerner Corp., BrainLab, Philips Healthcare, Prowess, Inc., DOSIsoft S.A., ViewRay Inc., MIM Software, and Flatiron are among the prominent players in the oncology information system market.

RECENT DEVELOPMENT:           

Varian Medical Systems, Inc. announced a USD 10.0 million investment and a strategic collaboration agreement with COTA, Inc., a curator of clinical data in the oncology sector, in 2020.

Siemens Healthineers (Germany) completed the acquisition of Varian Medical System in August 2021. (UK). The goal of this acquisition was to create a one-of-a-kind, highly integrated portfolio of oncology information system workflow.

Koninklijke Philips N.V. (The Netherlands) and Elekta (Sweden) will collaborate in June 2021 to develop advanced, comprehensive, and personalised cancer care through precision oncology information solutions.

McKesson Corporation (US) has launched Ontada, an oncology technology and insights business dedicated to advancing cancer research and care, in December 2020.

Key Segments 

By Product:

Solutions

Patient Information Systems

Treatment Planning Systems

Professional Services

By Application:

Medical Oncology

Radiation Oncology

Surgical Oncology

By Region:

North America

U.S.

Canada

Europe

U.K.

Germany

France

Italy

Spain

Asia Pacific

Japan

China

India

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Colombia

Middle East & Africa

Saudi Arabia

South Africa

UAE

[meditech-insights]

Single-Cell Analysis Market is set to be driven by the expansion of Oncology and Life Science Research

Single-cell technologies allow the examination of differences between individual cells instead of the averaged signal obtained is the case of bulk samples.

Global Single-Cell Analysis Market is estimated at $2.1 Bn (2020) growing at a CAGR of 17.8% through 2020-2025. The expansion of oncology and life science research is the factor driving the market growth.

Single-cell analysis: A potential oncology research tool

Single-cell analysis is emerging as powerful tool for cancer research. It characterizes the molecular state of each tumor cell, enabling exploration of tumor heterogeneity, microenvironment cell-type composition, and cell state transitions that affect therapeutic response, particularly in the context of immunotherapy. The demand for products used in single-cell analysis is projected to increase due to the increased incidence of various forms of cancer and the expansion of cancer research projects.

“Bulk sequencing can explain the most common mutations in tumor, but single-cell DNA multi-omics offer insights on which mutations occur at single-cell level. Drug developers are increasingly using single-cell analysis to prioritize targets and pathways for new therapies, demonstrate therapeutic efficacy, and understand resistance mechanisms” - Global Research Head, Leading Pharmaceutical Company

Investor funding is providing impetus for single-cell technology

Single-cell analysis has become a vital tool for scientific research. Investors are providing funding to companies that are developing products or solutions for single-cell analysis, citing the potential for advancement.

For instance,

In November 2021, Singleron Biotechnologies, a start-up company developing single-cell multi-omics products – raised $100 million to ramp up products development and augment international presence.

Further, in October 2021, Sphere Fluidics received $40 million to expand international sales activities for its single-cell analysis systems that use proprietary picodroplet technology.

Explore Premium Report on Single-Cell Analysis Market @ https://meditechinsights.com/single-cell-analysis-market/

Analysis of complex and richer datasets may present challenge

In comparison to bulk sequencing, single-cell sequencing methods generate datasets that are more complex and richer. The increased complexity might result in misunderstandings and wrong conclusions. However, advances in data analytics as well as the use of machine learning/AI to data analysis are increasingly being used to overcome these challenges.

Regional Adoption: Single-Cell Analysis Market

Comprehensive regional assessment of the global single-cell analysis market suggests that US is currently the largest market for single-cell analysis. The U.S. has a large number of biotech companies and research institutions, and it enjoys greater funding for life science research. Also, the U.S. led global VC investment in biotech sector in 2020, followed by Europe and China. The Asia-Pacific single-cell analysis market dominated by China is expanding more quickly compared to other regions.

Competitive Landscape Analysis of Single-Cell Analysis Market

Some of the key players in global single-cell analysis market are Becton, Dickinson and Company, Danaher, Merck, Thermo Fisher, Qiagen, 10X Genomics, Fluidigm, Promega, Illumina, Bio-Rad Laboratories, and Luminex.

For More Comprehensive Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com

[researchvishal]

Positron Emission Tomography (PET) Scanners Market Revenue, Future And Business Analysis By Forecast 2031

The global positron emission tomography (PET) scanners market growth was valued at over US$ 1.2 Bn in 2021 and is expected to exhibit a CAGR of close to 5.1% over the forecast period.

Key Takeaways:

By product, full-ring PET scanner is expected to hold over 86.2% of the total market share by 2031.

Sales in the oncology segment accounted for over 85.2% of market share in 2020, owing to the increasing incidence of chronic diseases and cancer.

Based on detector type, demand in the lutetium oxyorthosilicate (LSO) segment to held over 37.3% of market share in 2020.

Hospitals dominate end user segment with a share of around 34.9% in 2020 due to increasing patient inflow after COVID-19 outbreak.

The concept of PET as a nuclear medicine imaging technology was established in early 1970s. Ever since the technology has evolved into routine clinical imaging modality, revolutionizing the process of diseases diagnosis and management into more effective fashion.

PET is a molecular imaging technology that detects the concentration and pharmacokinetics of radiotracer molecules that are labelled with radioisotopes. This helps to diagnose and determine the severity of a various diseases such as neurological disorders, cardiovascular disorders, cancer, gastrointestinal and various others.

Based on the operational and geometrical capabilities of PET scanners, the systems are classified as full ring PET systems and partial ring PET systems. Advancements in technological performance of these systems are always associated with higher cost, limiting its widespread utilization in clinical PET imaging.

Rising prevalence of chronic disorders such as cancer and cardiovascular disorders, coupled with greater awareness towards physical wellbeing and limitations of conventional PET scanner is spurring demand for effective diagnostic techniques, thereby augmenting growth of the market.

PET scanners have continued to improve image quality and performance over the last few years. Technological improvements such as managing dose, reduced imaging time and enhanced lesion detectability have increased PET’s functionality, thus making it easier to interpret and diagnose various life-threatening disorders.

Key Market Segments Covered

By Product:

Full-ring PET scanner

Partial-ring PET scanner

By Application:

Oncology

Cardiology

Neurology

Others

By Detector Type:

Bismuth Germanium Oxide (BGO)

Lutetium Oxyorthosilicate (LSO)

Gadolinium Oxyorthosilicate (GSO)

Lutetium Fine Silicate (LFS)

Lutetium Yttrium Orthosilicate

By End User:

Hospitals

Diagnostic Centers

PET Centers

Research Institute

For more Information @ https://www.futuremarketinsights.com/reports/positron-emission-tomography-scanners-market 

“Ongoing technological advancements in PET scanners, copled with increasing applications in diagnostic centers and research institutes will propel the growth of the market in the forthcoming years” says a FMI analyst.

Who is winning?

Acquisitions, mergers, expansion, and product launches are the key strategies adopted by manufacturers to increase consumer base in different geographies. For instance:

In January 2020, Koninklijke Philips N.V. introduced its advanced solutions called Vereos Digital PET/CT (world’s first and only fully digital, clinically proven, PET/CT solution), an AI-powered solution for precision diagnosis at IRIA 2020.

[medi-techinsights]

Global Single-Cell Analysis Market valued at USD 2.1 billion (2020), is growing at a lucrative CAGR of 17.8% through the forecast period 2020-2025

Single-cell technologies enable the analysis of differences between individual cells instead of the averaged signal obtained is the case of bulk samples.

Single-Cell Analysis: A potential oncology research tool

Single-cell analysis is emerging as powerful tool for cancer research. It characterizes the molecular state of each tumor cell, enabling exploration of tumor heterogeneity, microenvironment cell-type composition, and cell state transitions that affect therapeutic response, particularly in the context of immunotherapy. With the growing prevalence of various types of cancers and rising cancer research projects, the demand for products used in single-cell analysis is likely to grow.

“Bulk sequencing can explain the most common mutations in tumor, but single-cell DNA multi-omics offer insights on which mutations occur at single-cell level. Drug developers are increasingly using single-cell analysis to prioritize targets and pathways for new therapies, demonstrate therapeutic efficacy, and understand resistance mechanisms” – Global Research Head, Leading Pharmaceutical Company

Investor funding is providing a huge impetus for single-cell technology

Single-cell analysis has emerged as an important tool for scientific research. Citing the growth potential, investors are funding companies who are developing products/solutions for single-cell analysis. For instance, in November 2021, Singleron Biotechnologies, a start-up company developing single-cell multi-omics products – raised $100 million to ramp up products development and augment international presence. Further, in October 2021, Sphere Fluidics received $40 million to expand international sales activities for its single-cell analysis systems that use proprietary picodroplet technology.

Analysis of complex and richer datasets may present future challenges

Single-cell sequencing methods generate more complex and richer datasets compared to bulk sequencing. This higher complexity may lead to misinterpretations and deriving wrong conclusions. However, these challenges are being increasingly addressed with advancements in data analytics as well as use of machine learning/AI in data analysis.

Geographic Snapshot: Global Single-Cell Analysis Market

Comprehensive regional assessment of the global single-cell analysis market suggests that US is currently the largest single-cell analysis market. The United States comprises of large number of biotech companies as well as research institutes and enjoys greater funding for life science research. Also, the U.S. led global VC investment in biotech sector in 2020, followed by Europe and China. The Asia-Pacific single-cell analysis market led by China is growing faster compared to other regions.

The main players operating in the global single-cell analysis market are Becton, Dickinson and Company, Danaher, Merck, Thermo Fisher, Qiagen, 10X Genomics, Fluidigm, Promega, Illumina, Bio-Rad Laboratories, and Luminex.

Get Customized Report on Single-Cell Analysis Market @ https://meditechinsights.com/single-cell-analysis-market/

[deshpandeisha]

Revolutionizing Cancer Treatment with Real World Evidence

The global real world evidence solutions for oncology market size reached USD 1.38 Billion in 2022 and is expected to register a revenue CAGR of 13.2% during the forecast period, according to the latest analysis by Emergen Research. The market revenue growth is significantly driven by the rising incidence of cancer. Increasing Real-World Evidence (RWE) and Artificial Intelligence (AI) integration in the healthcare sector is a key factor driving the market for clinical decision support systems.

The report focuses on current and future market growth, technological advancements, volume, raw materials, and profiles of the key companies involved in the market. The report provides valuable insights to the stakeholders, investors, product managers, marketing executives, and other industry professionals.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1772

Competitive Terrain:

The global Real World Evidence Solutions For Oncology industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Anthem, Inc.; IQVIA Inc.; ICON plc; Thermo Fisher Scientific Inc.; Clinigen Limited; Cognizant Technology Solutions Corporation; Oracle; Parexel International Corporation; PerkinElmer, Inc.; IBM Corporation

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Real World Evidence Solutions For Oncology market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Real World Evidence Solutions For Oncology market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Real World Evidence Solutions For Oncology market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1772

Market Segmentations of the Real World Evidence Solutions For Oncology Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Real World Evidence Solutions For Oncology market on the basis of product, application, and region:

Segments Covered in this report are:

Applications Outlook (Revenue, USD Billion; 2019-2032)

Breast Cancer

Lung Cancer

Others

Component Outlook (Revenue, USD Billion; 2019-2032)

Electronic Health Record (EHR)

Integrated dataset  

Others

Regional Outlook (Revenue, USD Billion; 2019–2032)

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

UAE

South Africa

Turkey

Rest of MEA

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/real-world-evidence-solutions-for-oncology-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1772

[marketnews2021]

The global CT Scanner market size is expected to reach USD 8.40 billion by 2027 according to a new study by Polaris Market Research. The report “CT Scanner Market Share, Size, Trends, Industry Analysis Report, By Type (Stationary and Portable CT Scanners); By Technology (High Slice, Mid Slice, Low Slice, and Cone Beam CT); By Architecture (C-arm and O-arm CT Scanners); By Application (Oncology, Neurology, Cardiovascular, Musculoskeletal, and Other Applications), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Computed tomography is an imaging devices which enables users to look inside the specimen without cutting it. It utilizes computer systems and rotating X-rays machines to produce cross sectional images. In medical, it offers images of blood vessels, bones, and soft tissues to find any ailments or bone fractures in the human body. CT scanning is non-invasive, fast, accurate, and painless procedure. In emergency situation, it provides details of internal injuries and hemorrhage, which saves many human lives.

Request for sample copy of this report @   https://www.polarismarketresearch.com/industry-analysis/ct-scanner-market/request-for-sample

The prominent factors favoring the market growth include improvement in the Scanner technology, miniaturization resulting in portable CT Scanner, and rising prevalence in bone-related disorders coupled with road traffic accidents. According to the statistics published by the U.S. Center for Disease and Control (CDC), around 30 million people take part in sports related activities in the U.S. alone. Of this, individuals aged 15 to 20 accounted for around 2 million injuries and more than 30,000 hospital admissions per year.

Moreover, many start-ups are employing artificial intelligence (AI) for an accurate diagnosis. According to the study published in NVIDIA, AI could significantly drop error rate in cancer diagnosis by more than 85 per cent. In line with this, Aidoc, an Israel based start up is employing AI to decipher medical scans and in 2016, the U.S. based AI medical imaging platform Behold.ai, came up with its proprietary “red dot algorithm”. This algorithm has 90 per cent accuracy and faster scanning capability.

Market participants such as CurveBeam, Hitachi Medical Corporation, Neusoft, Samsung, Canon Medical Systems, GE Healthcare, Medtronic Inc., Accuray, Koning Corporation, Xoran, Koninklijke Philips, Carestream, Planmed Oy, Siemens Healthineers, Shenzhen Anke High-Tech, and United Imaging Technologies are some of the key players operating in the concerned market.

Request for Discount on This Report  @   https://www.polarismarketresearch.com/industry-analysis/ct-scanner-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com